Immunotherapy Pipeline UBI focuses on immunotherapeutics and vaccines for chronic and infectious diseases, presenting opportunities to discuss strategic partnerships, co-development, or contract manufacturing for peptide-based therapies and vaccine platforms.

Synthetic Peptide Platform Proprietary designer peptide technology underpins diagnostics, a commercial peptide vaccine, and potential expansion into biosimilars and targeted therapeutics, suggesting cross-sell of peptide design, formulation systems, and manufacturing services.

Contract Manufacturing UBI-Asia provides pharmaceutical contract manufacturing, offering a clear avenue to present CDMO services to clients seeking scalable production for peptides, vaccines, or monoclonal antibodies.

Revenue Growth With revenue in the mid-range tens of millions, there is room to position value-led partnerships, grants, and sponsorship opportunities to accelerate pipeline milestones and diversify funding sources.

Biosimilar and Diagnostics UBI’s platform supports biosimilar development and blood screening diagnostics, presenting opportunities to explore collaboration on generic biologics pipelines and diagnostic assay development for partner portfolios.